Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
HHS, FDA Offer Timeline for Phasing Out Petroleum-Based Food Dyes
THURSDAY, April 24, 2025 -- The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration have released further details of their...
Young Women Show Greater Increase in Past-Month Binge Drinking Than Men
THURSDAY, April 24, 2025 -- The sex-based differences in past-month binge drinking among young adults reversed in 2021-2023 versus 2017-2019, with higher...
Single-Dose Baloxavir Treatment Can Reduce Influenza Transmission
THURSDAY, April 24, 2025 -- A single-dose baloxavir treatment can reduce influenza transmission from index patients to household contacts, according to a study...
School-Based Asthma Therapy Boosts Asthma Control, Cuts Acute Health Care Use
THURSDAY, April 24, 2025 -- School-based asthma therapy (SBAT) can help improve children’s asthma control and decrease acute health care utilization...
Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema
THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema...
Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
THURSDAY, April 24, 2025 -- Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD)...
FDA Warns of Unapproved Hair-Loss Product Linked to Side Effects
THURSDAY, April 24, 2025 — A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left them...
U.S. Births Barely Rise in 2024
THURSDAY, April 24, 2025 (Health Day News) — Fewer babies are being born in the U.S., and experts are worried what that portends for the future. The...
U.S. Faces Largest Measles Outbreak Since 2000
THURSDAY, April 24, 2025 — The United States is now experiencing its largest measles outbreak since the disease was declared eliminated in 2000, federal...
Anemia In Pregnancy Increases Risk Of Heart Defects
THURSDAY, April 24, 2025 -- Treating anemia during pregnancy might lower the risk of heart defects in newborns, a new study says. Women with anemia in early...
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and...
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.-- April 17, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome
Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the...
Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (diazepam nasal spray) in Ages 2 to 5 Years
San Diego, CA – April, 16, 2025 – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam...
Mirum’s Livmarli Now FDA Approved in Tablet Formulation
FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration...
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 3, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia
WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to...
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
PRINCETON, N.J. and TOKYO, JAPAN March 31, 2025 – Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd...
FDA Issues Complete Response Letter for Etripamil for PSVT
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug...
FDA Grants Priority Review for Biologics License Application (BLA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 25, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative...
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
PRINCETON, N.J.--(BUSINESS WIRE) Apr 22, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial evaluating the...
Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the...
BlueRock Therapeutics Announces Publication in Nature of 18-Month Data from Phase 1 Clinical Trial for Bemdaneprocel, an Investigational Cell Therapy for Parkinson’s Disease
Cambridge MA, USA, April 16, 2025 – BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today...
Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases
Tuesday, April 15, 2025 -- New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis...
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Apr. 15, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.